Practitioner's Docket No. MPI00-079P1RCP2CN1M

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Kindly cancel claims 13-15, 28, and amend claims 16, 17, 19, 23, 25, 26, 36, and 48 as follows: STATUS OF THE CLAIMS:

1.-12 Cancelled

13-15 (Cancelled)

- 16. (Currently amended) An antibody which selectively binds to a polypeptide of claim 13 43.
- 17. (Currently amended) A method for detecting the presence of a polypeptide of claim 13 43 in a sample comprising:
- a) contacting the sample with a compound which selectively binds to the polypeptide; and
- b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 13 in the sample.
- 18. (Previously presented) The method of claim 17, wherein the compound which binds to the polypeptide is an antibody.
- 19. (Currently amended) A kit comprising a compound which selectively binds to a polypeptide of claim 13-43 and instructions for use.

20.-22 Cancelled

- 23. (Currently amended) A method for identifying a compound which binds to a polypeptide of claim 13 43 comprising:
- a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and
 - b) determining whether the polypeptide binds to the test compound.
- 24. (Previously presented) The method of claim 23, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
 - a) detection of binding by direct detection of test compound/polypeptide binding;
 - b) detection of binding using a competition binding assay; and

Practitioner's Docket No. MPI00-079P1RCP2CN1M

- c) detection of binding using an assay for DHDR activity.
- 25. (Currently amended) A method for modulating the activity of a polypeptide of claim 13 43 comprising contacting the polypeptide or a cell expressing the polypeptide with an antibody a compound-which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
- 26. (Currently amended) A method for identifying a compound which modulates the activity of a polypeptide of claim 13-43 comprising:
 - a) contacting a polypeptide of claim 13-43 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
- 27. (Previously presented) The method of claim 26, wherein said activity is modulation of virus activity.

28.-34 Cancelled

- 35. (Previously presented) The method of claim 26, wherein said activity is modulation of cellular proliferation.
- 36. (Currently amended) A method for identifying a compound which modulates cellular proliferation comprising:
- a) contacting the polypeptide of claim 13 43, or a cell expressing the polypeptide with a test compound; and
- b) identifying the compound as a modulator of cellular proliferation by determining the effect of the test compound on the activity of the polypeptide.

37-42 Cancelled

- 43. (Previously presented) An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID No:5.
- 44 (Previously presented) The polypeptide of claim 43, further comprising heterologous amino acid sequences.

Practitioner's Docket No. MPI00-079P1RCP2CN1M

- 45 (Previously presented) An isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID No:5.
- 46 (Previously presented) An isolated polypeptide comprising the amino acid sequence of the polypeptide expressed from the plasmid deposited with ATCC as Accession Number PTA-1845.
- 47 (Previously presented) An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:5, wherein said polypeptide has a dehydrogenase activity.
- 48 (Currently amended) The polypeptide of claim 47, further comprising heterologous amino acid sequences.